Korea Investment CORP Sells 22,072 Shares of Amgen Inc. $AMGN

Korea Investment CORP reduced its holdings in Amgen Inc. (NASDAQ:AMGN) by 6.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 329,795 shares of the medical research company’s stock after selling 22,072 shares during the quarter. Korea Investment CORP owned approximately 0.06% of Amgen worth $93,068,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Legacy Investment Solutions LLC acquired a new stake in shares of Amgen in the second quarter valued at about $27,000. Evelyn Partners Investment Management LLP acquired a new position in shares of Amgen in the second quarter worth approximately $32,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen in the second quarter worth approximately $32,000. Cloud Capital Management LLC bought a new stake in Amgen in the third quarter valued at approximately $34,000. Finally, Nvwm LLC increased its position in Amgen by 893.3% during the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 134 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $369.53 on Friday. The stock has a market capitalization of $199.20 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 3.67 and a beta of 0.45. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock’s 50 day moving average price is $353.26 and its two-hundred day moving average price is $322.62.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. Amgen’s dividend payout ratio is currently 70.84%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY‑2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex‑dividend May 15), reinforcing shareholder returns and supporting income‑oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare‑disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short‑interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late‑stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Scotiabank began coverage on shares of Amgen in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 price objective on the stock. BMO Capital Markets increased their price objective on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. DZ Bank lifted their target price on shares of Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Finally, Leerink Partners restated a “market perform” rating and issued a $355.00 target price on shares of Amgen in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $354.17.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.